This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX
by Zacks Equity Research
LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX are included in this Analyst Blog.
UTHR vs. ESALY: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
5 Momentum Stock Bargains Hunters Would Love Chasing
by Debdutta Sinha
Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.
Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left
by Nalak Das
we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.
Zacks.com featured highlights United Therapeutics, StoneCo, Reinsurance Group of America and United Airlines
by Zacks Equity Research
United Therapeutics, StoneCo, Reinsurance Group of America and United Airlines have been highlighted in this Screen of The Week article.
4 Stocks With Upgraded Broker Ratings for Attractive Returns
by Swayta Shah
As brokers have a deeper insight into stocks, one must follow rating upgrades before investing. We select United Therapeutics (UTHR), StoneCo (STNE), Reinsurance Group of America (RGA) and United Airlines (UAL), as these have seen rating upgrades.
Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UTHR vs. ESALY: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
Humana (HUM) Issues $1.25B Senior Notes, To Lower Debt Level
by Zacks Equity Research
Humana (HUM) issues senior notes with the intent to procure funds to trim its escalating debt level.
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
by Zacks Equity Research
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
UTHR vs. CORT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTHR vs. CORT: Which Stock Is the Better Value Option?
Can United Therapeutics (UTHR) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
United Therapeutics (UTHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is iShares MSCI USA SmallCap Multifactor ETF (SMLF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMLF
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Tyvaso drive the top line in the quarter.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 37.92% and 4.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares MSCI USA SmallCap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Should iShares MSCI USA SmallCap Multifactor ETF (SMLF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMLF
ASRT or UTHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. UTHR: Which Stock Is the Better Value Option?
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
by Zacks Equity Research
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.